| ivabradine versus amlodipine | |||
| CL3-023 (15mg), 0 | ivabradine 7.5mg twice daily
versus amlodipine | double-blind Follow-up duration: 3 months | |
| CL3-023 (20mg), 0 | ivabradine 10mg twice daily
versus amlodipine | double-blind Follow-up duration: 3 months | |
| ivabradine 10mg versus placebo | |||
| Borer (CL2-009) 10mg, 2003 | Ivabradine 5 mg twice daily (10mg/d)
versus placebo | double blind Follow-up duration: 2 weeks | |
| ivabradine 10mg versus placebo on top of amlodipine | |||
| CL3-018 10mg, 3000 | ivabradine 5mg twice daily (10mg/d) versus placebo | Follow-up duration: 12 weeks | |
| ivabradine 15mg versus amlodipine | |||
| Ruzyllo (CL3-023) 15mg, 2007 | ivabradine 7.5mg twice daily versus amlodipine 10mg once daily | Patients with a >/=3-month history of chronic, stable effort-induced angina | double-blind Follow-up duration: 3 months |
| ivabradine 15mg versus atenolol | |||
| INITIATIVE (CL3-017, Tardif) 15mg, 2005 | ivabradine 5 mg bid for 4 weeks and then either 7.5 or 10 mg bid for 12 weeks
versus atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks | patients with stable angina | double-blind Follow-up duration: 16 weeks |
| ivabradine 15mg versus placebo (on top standard treatment) | |||
| BEAUTIFUL (angina subgroup), | ivabradine target dose of 7ยท5 mg twice a day
versus placebo | patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina | double blind Follow-up duration: 19 months (range 16-24) 33 countries |
| ivabradine 15mg versus placebo on top of amlodipine | |||
| CL3-018 15mg, 3000 | ivabradine 7.5mg twice daily (15mg/d) versus placebo | ||
| ivabradine 15mg versus placebo on top of atenolol | |||
| ASSOCIATE (Tardif), 2009 NCT00202566 | ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months (on top atenolol 50 mg/day )
versus placebo on top atenolol 50 mg/day | patients with stable angina receiving atenolol 50 mg/day or another beta-blocker at equivalent doses for at least 3 months | double blind Follow-up duration: 4 months 20 countries |
| ivabradine 20mg versus amlodipine | |||
| Ruzyllo (CL3-023) 20mg, 2007 | ivabradine 10mg twice daily versus amlodipine 10mg once daily | Patients with a >/=3-month history of chronic, stable effort-induced angina | double-blind Follow-up duration: 3 months |
| ivabradine 20mg versus atenolol | |||
| INITIATIVE (CL3-017, Tardif) 20mg, 2005 | ivabradine 5 mg bid for 4 weeks and then 10 mg bid for 12 weeks
versus atenolol 50 mg od for 4 weeks and then 100 mg od for 12 weeks | patients with stable angina | double-blind Follow-up duration: 16 weeks |
| ivabradine 20mg versus placebo | |||
| SIGNIFY, 2014 ISRCTN61576291 | ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. versus placebo | patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more | double-blind Follow-up duration: 27.8 mo (median) |
| Borer (CL2-009) 20mg, 2003 | ivabradine 10mg twice daily (20mg/d)
versus placebo | double blind Follow-up duration: 2 weeks | |
| ivabradine 5mg versus placebo | |||
| Borer (CL2-009) 5mg, 2003 | versus | double blind Follow-up duration: 2 weeks | |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
